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Abstract
A finely tuned balance between estrogens and androgens controls reproductive functions, and the last step of
steroidogenesis plays a key role in maintaining that balance. Environmental toxicants are a serious health concern, and
numerous studies have been devoted to studying the effects of endocrine disrupting chemicals (EDCs). The effects of EDCs
on steroidogenic enzymes may influence steroid secretion and thus lead to reproductive toxicity. To predict hormonal
balance disruption on the basis of data on aromatase activity and mRNA level modulation obtained in vitro on granulosa
cells, we developed a mathematical model for the last gonadal steps of the sex steroid synthesis pathway. The model can
simulate the ovarian synthesis and secretion of estrone, estradiol, androstenedione, and testosterone, and their response to
endocrine disruption. The model is able to predict ovarian sex steroid concentrations under normal estrous cycle in female
rat, and ovarian estradiol concentrations in adult female rats exposed to atrazine, bisphenol A, metabolites of methoxychlor
or vinclozolin, and letrozole.
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Introduction
Humans may be exposed to numerous chemicals that impact
endocrine activity, and notably alter androgen/estrogen balance
[1]. Among environmental chemicals, atrazine, vinclozolin,
methoxychlor, and bisphenol A were found to be of particular
concern. Atrazine, a triazine herbicide which has been widely used
in agriculture and is persistent in surface water, has been described
in several in vitro studies to increase estrogen through elevation of
aromatase levels and activity [2,3]. The fungicide vinclozolin has
been documented for the anti-androgenic activity of its metabolite
M2 in vitro [4] and in vivo [5]. Methoxychlor is an organochlorine
pesticide of known estrogenic activities in vitro and in vivo [6]; its
metabolite 2, 2-bis-(p-hydroxyphenyl)-1, 1, 1-trichloroethane
(HPTE) displays estrogenic, anti-estrogenic, and anti-androgenic
capacities in vitro [7]. Bisphenol A, a plasticizer, was clearly defined
as an estrogenic agent due to its capacity to bind estrogen receptor
with an EC50 in the sub-micromolar range [8]. As far as drugs are
concerned, a good example of pharmacologically-designed endo-
crine modifier may be letrozole [9]. This potent and highly specific
nonsteroidal competitive aromatase inhibitor, used for estrogen-
dependent breast cancer, has been characterized by a half
maximal inhibitory concentration (IC50) of 7 nM [10].
A potential target for endocrine disrupting chemicals (EDCs) is
steroidogenesis. In females, sex steroids are synthesized primarily
in the ovaries and derived from cholesterol through a series of
biochemical reactions [11]. Among steroidogenic enzymes,
cytochrome P450 aromatase (Cyp19), which catalyses the final
irreversible conversion of androgens to estrogens in granulosa cells
(GCs), appears to be a key target. Aromatase disruption is often
associated with EDC toxicity [12], and several assay guidelines
recommend testing chemicals for that endpoint [13]. Aromatase
expression is regulated by follicle-stimulating hormone (FSH),
through multiple signaling pathways including cyclic adenosine
monophosphate (cAMP)-dependent regulatory events [14]. In
GCs, the final steps of steroidogenesis are also mediated by 17b-
hydroxysteroid-dehydrogenases (Hsd17b1 and Hsd17b2), which
catalyze the conversion of inactive sex steroids to active ones via
Hsd17b1 or vice-versa by Hsd17b2 [15].
Assessing EDC toxicity is a challenge, given the complexity of
the endocrine system and despite the increasing development of
data on its workings. Most standardized ‘‘regulatory’’ tests
developed to study EDC toxicity involve rats. Those in vivo tests
naturally integrate hormone metabolism and feedback loops. They
typically look at relevant integrated toxicity endpoints, such as
impact on fertility [16]. In vitro models have also been extensively
developed: they are faster, cheaper, and they spare animal lives
[17]. They help the researcher to elucidate toxic mechanisms in a
simple isolated system and, when performed on human cells, they
avoid difficult interspecies transpositions.
Both characterization and quantification of toxicity mechanisms
are necessary for a reliable quantitative in vitro to in vivo
extrapolation (QIVIVE) [18]. In order to improve QIVIVE for
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endocrine toxicity, we developed and parameterized a dynamic
systems biology model of the final steps of steroidogenesis in rat
ovaries. We calibrated our mathematical model in a Bayesian
framework on the basis of in vitro experimental data obtained from
rat granulosa primary cell cultures. For cross-validation, the in vitro
model was transposed to an in vivo context and predictions were
compared with in vivo hormone dosage data obtained in control
animals. We finally used our model to predict the effects of five
selected EDCs on gonad estradiol (E2) secretion, based on in vitro
data following exposure to atrazine, bisphenol A, methoxychlor
metabolite HPTE, vinclozolin metabolite M2, and letrozole.
These chemicals were chosen based on their known endocrine
activity in vitro and in vivo.
Materials and Methods
Test Chemicals
Atrazine (CAS number 1912-24-9, purity 97.1%) was provided
by TCI Europe (Zwijndrecht, Belgium); methoxychlor (CAS
number 72-43-5, purity .95%), HPTE (CAS number 2971-36-0,
purity 97%), and bisphenol A (CAS number 80-05-7, purity 99%)
were purchased from Sigma Aldrich Chemical Co. (Saint-
Quentin-Fallavier, France); vinclozolin (CAS number 50471-44-
8, purity 99.5%) was from Greyhound Chromatography (Birken-
head, UK); vinclozolin M2 (CAS 83792-61-4, purity .98%) was
from Interchim (Montluc¸on, France).
In Vitro Experiments
Rat GC isolation and in vitro culture. Immature (21 days
old) Sprague-Dawley female rats (certified virus-free) were
purchased from Janvier (Le Genest-Saint-Isle, France). They were
housed with a 12 h light and 12 h dark cycle and received food
and water ad libitum. All procedures were reviewed and approved
by the Institutional Animal Care and Use Committee of INERIS.
All animals were 26 days old at the start of treatment. Each animal
was injected subcutaneously with diethylstilbestrol (DES; Sigma
Aldrich Chemical Co., Saint-Quentin-Fallavier, France) dissolved
in corn oil (100 mg/0.1 ml) every day for 3 days to increase the
number of GCs. On the third day, the animals were sacrificed by a
lethal intraperitoneal pentobarbital injection. Five animals were
sacrificed for each experiment. The ovaries were harvested, and
the associated fat, oviduct, and bursa ovary removed; the samples
were placed in ice-cold medium 199 (M199; Sigma Aldrich), and
punctured several times with a 26-gauge needle until the antral
follicles ruptured and released the GCs. The GC-rich medium was
centrifuged (200 g) for 5 min to obtain a GC pellet, which was
resuspended in Dulbecco’s modified Eagle medium/Ham’s F-12
nutrient mix (DMEM/F-12; Sigma Aldrich) containing 5% fetal
bovine serum, 100 mg streptomycin per ml, and 100 IU penicillin
per ml. The cells (300,000/ml) were plated into 12-well culture
plates (2 ml/well)), and grown at 37uC in a humidified atmosphere
with 5% CO2. The cells were allowed to attach for 72 h prior to
treatment to minimize any effects due to in vivo DES priming [19].
GC treatment. We performed two experimental studies: a
baseline (control) study with measurements at 4 h, and an ‘‘EDC
study’’ with control (0.1% dimethyl sulfoxide, DMSO, in serum-
free and phenol red-free culture medium) and four chemicals
(atrazine, bisphenol A, HPTE, and vinclozolin M2) at 10 mM in a
final concentration of 0.1% DMSO culture medium, with
measurements at 4 h. The chemical concentration was chosen
on the basis of relevant literature [20]. Cellular viability was
determined by trypan blue exclusion staining, visual inspection for
morphology, and cellular attachment.
mRNA level and direct aromatase activity
measurements. mRNA levels and direct aromatase activity
were quantified according to previously described methods [20].
Briefly, mRNA was extracted from the cells then reverse
transcribed. Target fragments were amplified by real-time
polymerase chain reaction. Aromatase enzymatic activity was
measured on microsomal fractions of GCs with the tritiated water
release assay [21]. These experimental data were expressed as
‘‘fold difference’’ between treated and control conditions. Differ-
ences of single doses from controls were statistically analyzed with
a Mann-Whitney non-parametric test. Differences with a P value
of less than 0.05 were considered to be statistically significant.
In Vivo Experiments
The female Sprague-Dawley rats used were approximately 8
weeks old at the start of chemical exposure. Estrous cycle staging
was done with vaginal smears collected twice a day and classified
microscopically as diestrus, proestrus, estrus, or metestrus [22]. We
performed two experimental studies: a baseline (control) study,
measuring ovarian steroid concentrations across the estrous cycle,
and an ‘‘EDC study’’ where each animal in diestrus stage was
administered a test chemical or vehicle by gavage (atrazine
200 mg/kg, dissolved in 0.5% methylcellulose; bisphenol A or
methoxychlor at 200 mg/kg, dissolved in corn oil; vinclozolin
100 mg/kg, dissolved in corn oil). The animals were sacrificed six
hours after treatment; ovaries were harvested, weighed, and
homogenized in PBS-buffered water for tissue dosages. Atrazine,
bisphenol A, methoxychlor metabolite HPTE, vinclozolin metab-
olite M2, testosterone (T), androstenedione (A), estrone (E1), and
E2 were detected and quantified in whole ovaries by liquid
chromatography with tandem mass spectrometry detection (LC–
MS/MS) [23]. Differences between treated and control animals
were statistically analyzed with a Mann-Whitney non-parametric
test. Differences with a P value of less than 0.05 were considered to
be statistically significant.
Model Chemical
We choose to include an additional compound to further test
and cross-validate our mathematical model. Letrozole appeared to
be a very good choice, in the sense that it is pharmacologically
designed to specifically inhibit aromatase, which is one of the main
target described in our computational model. This compound was
not tested on our in vitro and in vivo systems, but experimental data
were gathered from the literature [10,24].
Mathematical Model Development
Model overview. The model describes the final metabolic
and transport steps of the steroidogenesis pathways in rat GCs
(Figures 1 and 2). Metabolic steps include synthesis and
degradation of Cyp19, Hsd17b1, and Hsd17b2 mRNAs and
proteins, conversion of A into T, E1, and E2, and modulation of
steroidogenic enzyme expression by FSH or an EDC. In vitro,
transport includes GC uptake and secretion of A, T, E1, and E2. In
vivo, transport also includes entry of A and T in ovaries, and
exchange of hormones between extracellular space, GCs, and
other kinds of cells (Figure 2).
Metabolic reactions. mRNA and protein synthesis. Cyp19 and
Hsd17b1 mRNA quantities in GCs (emRNA in pg/cell, with
e=Cyp19, Hsd17b1, or Hsd17b2) depend on their synthesis with
baseline rate nmRNA,e (pg/min). This rate is eventually altered by an
EDC X (inducing fold-change fX (unitless)), upregulated by FSH
(pg/cell) (with slope factors k (/pg FSH), and affected by
experimental variability (due to differences in cell pre-treatment,
modeled by a variability factor sL (arbitrary unit)); mRNA levels
In Silico Model of Rat Ovarian Steroidogenesis
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Fold-change for species emRNA was obtained from experimentally







In contrast, the Hsd17b2 mRNA quantity in GCs is not
assumed to be strongly controlled by FSH [25] nor affected by




For the three enzymes e (in pg/cell), the following mass-balance
equation, with synthesis rate constant nprot,e (/min) and degradation




Our experiments on GCs [20] gave us Hsd17b1 and Hsd17b2
initial mRNA and protein quantities, relative to Cyp19. We
translated them to absolute values (pg/cell) on the basis of the initial
quantities of Cyp19 mRNA and protein in GCs obtained from the
literature (Table 1). We assumed that these values were steady-state
values, in the absence of FSH stimulation, EDC alteration, or
experimental variability. Values for the mRNA and protein
degradation rate constants (dmRNA,e and dprot,e) were found in the
literature (Table 2). Using the above steady-state assumption, we set
equations 1, 2, and 4 for mRNA quantities, and equation 5 for
protein quantities, equal to zero and rearranged them for nmRNA.e
Figure 1. Overview of the computational model for steroidogenesis last metabolic steps in a rat granulosa cell. The transcription and
translation events for the three last major enzymes involved in estradiol synthesis, and sex steroid synthesis itself, are modeled, with relevant FSH
control, endocrine disrupting chemical (EDC) modulation, or methoxychlor (MXC) aromatase competitive inhibition. Steroids can be transported in
and out of cell. In vitro, the exterior compartment corresponds to the culture medium; in vivo it corresponds to the ovary tissue (see Figure 2). Aliases
(repeated species labels) are used for clarity but correspond in fact to a unique species.
doi:10.1371/journal.pone.0053891.g001
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and nprot.e. The value of nmRNA.e was computed for the three enzymes
e as:
vmRNA:e~emRNA,t~0:dmRNA ð6Þ
Similarly, assuming that one mRNA gets translated into one





Table 1. Granulosa cell specific mRNA and protein initial values used.
Initial values Name Experimental data (ratio to aromatase) Value (pg/cell)
Aromatase mRNA quantity Cyp19mRNA 1 4.96610
28a
Hsd17b1 mRNA quantity Hsd17b1mRNA 2.07 1.03610
27b
Hsd17b2 mRNA quantity Hsd17b2mRNA 0.14 7.00610
29b
Aromatase protein quantity Cyp19 1 0.1c
Hsd17b1 protein quantity Hsd17b1 2.1 0.21b
Hsd17b2 protein quantity Hsd17b2 0.14 0.014b
aHarada et al., 1999 [45].
bValues obtained from our relative in vitro data and the absolute values found in the literature for aromatase (see text).
cAuvray et al., 2002 [46].
doi:10.1371/journal.pone.0053891.t001
Table 2. Model parameter values (for one cell) obtained from direct measurements on granulosa cells in vitro or from the
published literature values.
Parameter (units) Symbol Value
mRNA degradation (/min) dmRNA 6.00610
23a
protein degradation (/min) dprot 3.00610
23a
Aromatase mRNA synthesis (pg/min) umRNA.Cyp19 3.00610
210b
Hsd17b1 mRNA synthesis (pg/min) umRNA.Hsd17b1 6.00610
210b
Hsd17b2 mRNA synthesis (pg/min) umRNA.Hsd17b2 4.20610
211b
Aromatase protein synthesis (/min) uprot.Cyp19 6000
b
Hsd17b1 protein synthesis (/min) uprot.Hsd17b1 6300
b
Hsd17b2 protein synthesis (/min) uprot.Hsd17b2 6000
b
Maximal reaction rates Vmax (pmoles/min/pg enzyme)
Hsd17b2, T R A reaction lHsd17b2,T 6.65610
28c
Hsd17b2, E2 R E1 reaction lHsd17b2,E2 7.91610
28c
Michaelis-Menten constants (pmoles)
Hsd17b2, for T jHsd17b2,T 5.67610
26c
Hsd17b2, for E2 jHsd17b2,E2 5.40610
26c
A extra- over intra-cellular partition coefficient (unitless) Roi,A 0,0124
d
T extra- over intra-cellular partition coefficient (unitless) Roi,T 0,013
d
E1 extra- over intra-cellular partition coefficient (unitless) Roi,E1 0,0084
d
E2 extra- over intra-cellular partition coefficient (unitless) Roi,E2 0,0108
d
A excretion rate constant (ml/min) Kout,A 1610
28e
T excretion rate constant (ml/min) Kout,T 1610
28e
E1 excretion rate constant (ml/min) Kout,E1 1610
28e
E2 excretion rate constant (ml/min) Kout,E2 1610
28e
Ovary blood flow (ml/min) Fov 0.2654
f
Individual granulosa cell volume (ml) VGC 0.27610
29 mlg
A, androstenedione; T, testosterone; E1, estrone; E2, estradiol.
aHargrove, 1993a [47]; Hargrove, 1993b [48].
bmRNA and protein synthesis rates were calculated under steady-state assumption with data from direct measurements on granulosa cells in vitro (see text).
cRenwick et al., 1981 [49].
dBreen et al., 2009 [26].
eData were arbitrately fixed.
fPlowchalk and Teeguarden, 2002 [50].
gDirect in vitro measurement.
doi:10.1371/journal.pone.0053891.t002
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Steroid biotransformation. The relevant enzymatic reac-
tions in GCs, catalyzed by Cyp19, Hsd17b1, and Hsd17b2, were
modeled by the following competitive Michaelis-Menten meta-
bolic terms ai, where le,Z (pmoles/min/pg enzyme) and je,Z
(pmoles) denote respectively Vmax and Km parameters for enzyme e
and substrate Z (A, T, E1, or E2).
Methoxychlor metabolite HPTE inhibits aromatase activity
directly and competitively [20]. To model that effect, the
parameter fM in equations 9 and 12 below represents the fold-
change of the aromatase Km for its substrate Z (jCyp19,Z), observed
in vitro. Since aromatase activity is inversely proportional to its Km,
this fold-change fM corresponds to the inverse of fold-change for
aromatase enzymatic activity between treated and control cells.





Measured aromatase activity in control cellst
Measured aromatase activity in treated cellst
ð8Þ
The conversion of A into E1 by aromatase takes into account T
competition for the enzyme (the steroids are subscripted with GC,


























































In order to model the isotopic measurement of tritiated water
(T2O) production during the conversion of tritiated A to E1 (see





The parameters of the above equations are listed in Table 2.
Transport kinetics. The model was first developed to
simulate in vitro conditions, and then adapted to model in vivo
conditions. While the GC internal workings remained the same,
different exchanges with the environment had to be described
(Figure 2).
Transport kinetics in vitro. The in vitro model is divided in two
compartments: GCs and culture medium (Figure 2A). For A
(pmoles), T (pmoles), E1 (pmoles), E2 (pmoles), and FSH (pg),
simple diffusion kinetics were assumed. The hormone quantity in a










where Kin,X (ml/min) is the rate of medium (‘‘med’’) uptake by the
GC, Kout,X (ml/min) the rate of excretion by the GC, Xmed (pmoles
or pg) the hormone quantity for one GC in the medium (total
quantity divided by the number of cells used in a given assay), Vmed
(ml) the volume of culture medium for one GC (total volume
divided by the number of cells), and VGC (ml) the volume of one
GC. Kin,X was computed by dividing Kout,X by the extra- over intra-






Conversely, the hormone quantity for one cell in the medium










The cellular kinetics of A, T, E1, and E2 quantities depend on
the entry in and exit from the cell and on their metabolism by
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where the ai are the Michaelis-Menten metabolic terms described
in equations 9 to 14. The diffusion and transport of T2O in the
in vitro system was not modeled, as the total quantity of T2O
formed was directly measured.
Transport kinetics in vivo. For in vivo simulations (Figure 2B), the
ovary was subdivided into three compartments: GCs, thecal and
interstitial cells (‘‘others’’), and extracellular/vascular space
(‘‘ext’’). The transport kinetics of hormone X in each cellular
compartment depend on entry rate constant (Kin) and exit rate
constant (Kout) for a cell, on the hormone concentrations in each
cell, and on the number of cells (NGCs or Nothers). The differential



















where Vext and Vothers are the volumes of the extracellular and
‘‘other cell’’ compartments, respectively.


















where Qinput,X (pmoles or pg/min) is the rate of input of hormone X
in the ovary (coming from blood), Fov (ml/min) the efflux of X from
the ovary (clearance by blood flow), and Vov,diestrus the ovarian
volume at diestrus (which was set at 0.05 ml [27]). For mimicking
the female estrus cycle in vivo, Qinput,X for FSH and androgens were
modeled as cyclic forcing functions, which were adjusted to give
ovarian concentrations matching our in vivo physiological obser-
vations (see Figure 3). Qinput,X is determined as:
Qinput,X~Qbase,XzQscale,X
:Qshape,X ð26Þ
where Qbase,X (pmoles or pg/min) is the constant baseline
concentration of hormone X, Qscale,X (unitless) the constant scale
for hormone X magnitude, and Qshape,X (pmoles or pg/min) the
variable magnitude of hormone X (adjusted to match the known
hormone concentrations).
The time courses of NGCs, Vext, and Vothers during the estrous cycle
were also modeled by forcing functions. The intracellular kinetic
equations of the various hormones were the same as in the in vitro
model (see metabolic reaction section).
Parameter value assignment and model
calibration. Whenever possible, the model parameters were
set to meaningful and physiologically based values that we directly
measured in vitro or that we found in the published literature
(Table 2).
The remaining model parameters (Table 3) were calibrated
using in vitro experimental data that we developed ourselves (see
above, in vitro data section), or that were published in the literature
(Information S1). A Bayesian numerical approach, Markov Chain
Monte Carlo (MCMC) simulations [28], was used.
The published in vitro data we used to calibrate the model
included different cell pre-treatment protocols, which induced a
large inter-study variability in baseline transcription rates nmRNA.e.
That random effect was modeled with a variability factor sL (see
equations 1, 2, and 4), assumed to be log-normally distributed
around a mean ms, with variance S1. The hyperparameters ms and
S1 were in turn assigned vague prior distributions (Table 3). The
individual random effects sL (one per data set used, see
Information S1), ms, and S1 were calibrated together with the
other parameters.
Figure 2. Overview of the compartments used to model in vitro (A) or in vivo (B) hormone transports. In vitro (A), the exterior
compartment corresponds to the culture medium. In vivo (B), the ovary tissue is subdivided into three compartments: granulosa cells, ‘‘other cells’’ for
thecal and interstitial cells, and extracellular space.
doi:10.1371/journal.pone.0053891.g002
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Figure 3. Experimental data vs predictions for FSH and sex steroid hormones in normal cycling rat. The black line represents mean
model predictions with 95% confidence interval (grey band); points represent our experimental observations (mean of 10 measurements 6 standard
deviation).
doi:10.1371/journal.pone.0053891.g003
In Silico Model of Rat Ovarian Steroidogenesis
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The other parameters to be calibrated were assigned a prior
distribution (Table 3). We mostly used lognormal distributions
with geometric means set at physiologically relevant values. The
geometric standard deviations were set to 2 or 1.2 for the
parameters for which we had better information (Table 3). The
data likelihoods were assumed to follow a lognormal distribution
around the model predictions, a standard assumption with such
measurements. The measurement error variances, which were
assumed to be different between mRNA/protein quantities (S2)
and hormone measurements (S3) (Table 3), were calibrated
together with the other (physiological) parameters. A total of 24
parameters (11 physiological and 13 statistical) were MCMC
sampled.
MCMC simulations (Metropolis-Hastings algorithm) were
performed in triplicate chains of 20,000 iterations. For each
model parameter sampled, convergence was evaluated using the
last 10,000 iterations from each chain and the potential scale
reduction criterion ^R of Gelman and Rubin [29].
Flux Analyses of In Vitro and In Vivo Experiments
Maximum a posteriori probability estimates of the calibrated
parameters (Table 4) were used to do metabolic flux analyses [30],
computing the rate of each steroid biotransformation reaction (a1
to a6, equations 9 to 14) as a function of time, to determine the
predominant reactions for the conversion of A to E2.
Model Cross-validation Using In Vivo Data
In order to evaluate the predictive capacities of the model, we
used random parameter vectors from their joint posterior
distributions obtained by calibration with in vitro data (Table 4),
and some other parameter distributions (Table 5), to simulate
in vivo conditions. Table 5 includes parameters which were not
calibrated from in vitro data because reasonable values were
obtained for them in the literature, but which nonetheless have
in vivo variability. We then simply compared the model predictions
to the corresponding in vivo data. The cyclic entries of androgens
and FSH in GCs and the time-varying number of ovarian cells
were modeled as described in section ‘‘Transport kinetics in vivo’’.
Predictive Simulations of Endocrine Disruption
To evaluate the capacity of the above model to predict in vivo
effects of EDCs on E2 secretion on the basis of in vitro data, we ran
a series of simulations of endocrine disruption by atrazine,
bisphenol A, methoxychlor metabolite HPTE, vinclozolin metab-
olite M2, and letrozole over two estrous cycles. The mRNA and
Km fold-changes fX (equations 1–3, 8, 9, and 12) were changed to
their experimentally observed values (see Table 6), starting eight
hours after the beginning of the second modeled diestrus. We then
compared the in vivo E2 quantities measured experimentally in
EDC-treated females in diestrus with the model predictions. The
hypothesis that the distributions of experimental data and model
Table 3. Prior distributions of the model parameters (for one granulosa cell) to be calibrated by MCMC sampling.
Parameter (units) Symbol Prior distribution
FSH effect on aromatase mRNA transcription (/pg FSH) kCyp19 U (0, 1610
7)a
FSH effect on Hsd17b1 mRNA transcription (/pg FSH) kHsd17b1 U (0, 1610
6)a
Maximal reaction rates Vmax (pmoles/min/pg enzyme)
Aromatase
A R E1 reaction lCyp19,A LN (1.33610
27, 1.2)a,b,c,d
T R E2 reaction lCyp19,T LN (1.33610
27, 2.0)d
Hsd17b1
A R T reaction lHsd17b1,A LN (7.59610
28, 2.0)e,f,g




For A jCyp19,A LN (8.10610
29, 1.2) a,b,c,d
For T jCyp19,T LN (3.24610
28, 2.0)d
Hsd17b1
For A jHsd17b1,A LN (4.32610
25, 2.0) e,f,g
For E1 jHsd17b1,E1 LN (5.29610
26, 2.0) e,f,g
Mean inter-study random effect (arbitrary unit) m0 LN (1, 2.0)
Measurement variance for inter-study random effects S1 HN (0.5)
Measurement variance for data likelihood of mRNA and proteins S2 HN (0.2)
Measurement variance for data likelihood of hormone measurements S3 HN (0.2)
LN (geometric mean, geometric SD): lognormal distribution; U (min, max): uniform distribution; HN (SD): halfnormal distribution with mean at zero.
Prior distribution for Vmax and Km parameters and for FSH effects are obtained and estimated from direct measurements on granulosa cells in vitro.
aQuignot et al., 2012a [20].
bOdum et al., 2001 [51].
cAuvray et al., 2002 [46].
dKrekels et al., 1990 [52].
eIshikura et al., 2006 [53].
fRenwick et al., 1981 [49].
gSteckelbroeck et al., 2003 [54].
doi:10.1371/journal.pone.0053891.t003
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predictions were identical was statistically tested with a two-sample
Kolmogorov-Smirnov test [31]. Differences with a P value of less
than 0.05 were considered to be statistically significant.
Software Used
Cell Designer 4.2 [32] was used to produce Figure 1. Model
simulations, MCMC simulations for model calibration, and flux
analyses were performed with GNU MCSim v5.4.0 [28].
Statistical analyses and plots were performed with R, version
2.14.0 [33].
Results
In Vitro Experimental Results
To evaluate and quantify how the selected EDCs affect
aromatase and Hsd17b mRNA levels, as well as aromatase
function, we exposed rat primary GCs (or microsomal fractions for
direct aromatase activity) to atrazine, bisphenol A, methoxychlor
metabolite HPTE, or vinclozolin metabolite M2. The chemical
concentration used corresponded to the highest one found in rat
ovaries following oral exposure to a high dose of each selected
EDC [23]. None of the chemicals tested affected cell viability, as
assessed with trypan blue exclusion staining and morphological
evaluation. The purpose for measuring aromatase activity on
microsomes (rather than in entire cells) was to discriminate a direct
effect of chemicals at the functional protein level from an effect
due to altered protein levels. Table 6 illustrates the fold-changes
(relative to appropriate controls) for aromatase direct enzymatic
activity, and aromatase and Hsd17b1 mRNA level modulation. In
our experiments, Hsd17b2 mRNA levels were too low to be
quantified. Atrazine, bisphenol A, and vinclozolin metabolite M2
did not affect aromatase direct activity, whereas HPTE decreased
it by 11%.
Atrazine increased aromatase and Hsd17b1 mRNA levels with
fold-inductions of 1.94 and 3.04, respectively. Bisphenol A
increased 1.61-fold the amount of aromatase mRNA levels, but
did not modify the Hsd17b1 mRNA levels. HPTE did not affect
aromatase or Hsd17b1 mRNA levels. Vinclozolin up-regulated
3.13 and 1.61-fold aromatase and Hsd17b1 mRNA levels,
respectively.
Experimental in vitro data for letrozole were found in the
literature [10]. Hence, at the concentration of 50 nM, which
corresponds to that found in rat ovaries after treatment with
letrozole at 5 mg/kg, aromatase activity was decreased to 29%
compared to control.
In Vivo Experimental Results: Baseline Study
Gonadal sex steroid and blood FSH concentrations in healthy
cycling female rats were measured at several times, falling in





estimates 0.5 percentile 2.5 percentile 97.5 percentile 99.5 percentile
kCyp19 2.08610
6 4.046105 2.086106 1.206106 1.366106 2.976106 3.276106
kHsd17b1 4.55610
5 1.766105 6.046105 1.086105 1.596105 8.516105 9.386105
lCyp19,A 1.04610
27 1.7861028 1.0761027 6.5461028 7.3661028 1.4461027 1.5961027
lCyp19,T 3.72610
27 2.1661027 2.6761027 8.3961028 1.1561027 9.6161027 1.3361026
lHsd17b1,A 1.03610
27 7.8661028 5.6561028 1.3061028 2.1261028 3.1461027 4.7661027
lHsd17b1,E1 3.22610
25 1.9861025 1.7861025 6.5961026 9.4261026 8.5761025 1.0661024
jCyp19,A 8.32610
29 1.5361029 8.2561029 5.1661029 5.761029 1.1761028 1.3261028
jCyp19,T 4.12610
28 3.1861028 1.2461028 5.5561029 8.2961029 1.2461027 1.761027
jHsd17b1,A 6.49610
25 4.9361025 4.8461025 9.5861026 1.3861025 1.9861024 2.7461024
jHsd17b1,E1 2.91610
26 1.9661026 1.3061026 4.7461027 6.6161027 8.0061026 1.1261025
m0 0.407 0.163 1.46 0.131 0.177 0.81 1.08
S1 1.43 0.295 0.265 0.803 0.911 2.07 2.24
sL1 1.07 2.1 0.117 0.0144 0.0367 5.42 19
sL2 1.86 0.817 1.99 0.552 0.728 3.85 5.1
sL3 0.0376 0.0181 0.0293 0.0109 0.0143 0.0839 0.116
sL4 0.0314 0.0148 0.0193 0.00923 0.0122 0.0667 0.0938
sL5 4.78 2.94 2.86 1.12 1.47 12.3 18.6
sL6 0.028 0.0127 0.0213 0.00912 0.0111 0.0612 0.0808
sL7 0.158 0.0306 0.153 0.0938 0.107 0.226 0.259
sL8 0.696 0.422 0.612 0.129 0.188 1.75 2.48
sL9 0.971 1.63 0.114 0.0182 0.0329 4.88 11.7
sL10 0.685 0.101 0.685 0.46 0.506 0.916 1.03
S2 0.648 0.0842 0.626 0.47 0.503 0.832 0.901
S3 0.48 0.111 0.501 0.251 0.29 0.752 0.802
Each sLi corresponds to the specific inter-study random effect sL for each simulation set described in Information S1.
doi:10.1371/journal.pone.0053891.t004
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different periods of the estrous cycle (Figure 3). Those results are
well in agreement with the published scientific literature [34].
Model Calibration
Twenty-four model parameters were jointly calibrated using
MCMC simulations. The three chain simulations converged after
10,000 iterations ( ^R was at most 1.01 for all sampled parameters).
The posterior fit after parameter Bayesian calibration has an
average absolute deviation of 18.82% between data and predic-
tions.
Table 4 presents summary statistics of the posterior distributions
for the parameters calibrated. Those statistics are based on 30,000
Table 5. Model parameter distributions used to describe in vivo variability (in addition to those of Table 4).
Parameter (units) Symbol Prior distribution
FSH dose rate: base concentration Qbase,FSH LN (330, 1.2)
FSH dose rate: scale concentration Qscale,FSH LN (1450, 1.2)
A dose rate: base concentration Qbase,A LN (1.2, 1.2)
A dose rate: scale concentration Qscale,A LN (18, 1.2)
T dose rate: base concentration Qbase,T LN (3, 1.2)
T dose rate: scale concentration Qscale,T LN (13, 1.2)
Ovary blood flow (ml/min) Fov LN (0.2654, 1.1)
A excretion rate constant (ml/min) Kout,A LN (1610
28, 2.0)
A extra- over intra-cellular partition coefficient (unitless) Roi,A LN (0.0124, 1.2)
T excretion rate constant (ml/min) Kout,T LN (1610
28, 2.0)
T extra- over intra-cellular partition coefficient (unitless) Roi,T LN (0.0130, 1.2)
E1 excretion rate constant (ml/min) Kout,E1 LN (1610
28, 2.0)
E1 extra- over intra-cellular partition coefficient (unitless) Roi,E1 LN (0.0084, 1.2)
E2 excretion rate constant (ml/min) Kout,E2 LN (1610
28, 2.0)
E2 extra- over intra-cellular partition coefficient (unitless) Roi,E2 LN (0.0108, 1.2)
mRNA degradation (/min) dmRNA LN (0.006, 1.2)
protein degradation (/min) dprot LN (0.003, 1.2)
Aromatase mRNA synthesis (pg/min) umRNA.Cyp19 LN (3610
210, 1. 2)
Hsd17b1 mRNA synthesis (pg/min) umRNA.Hsd17b1 LN (6610
210, 1. 2)
Hsd17b2 mRNA synthesis (pg/min) umRNA.Hsd17b2 LN (4.2610
211, 1. 2)
Aromatase protein synthesis (/min) uprot.Cyp19 LN (6000, 1.2)
Hsd17b1 protein synthesis (/min) uprot.Hsd17b1 LN (6300, 1.2)
Hsd17b2 protein synthesis (/min) uprot.Hsd17b2 LN (6000, 1.2)
Maximal reaction rates Vmax (pmoles/min/pg enzyme)
Hsd17b2, T R A reaction lHsd17b2,T LN (6.65610
28, 2.0)
Hsd17b2, E2 R E1 reaction lHsd17b2,E2 LN (7.91610
26, 2.0)
Michaelis-Menten constants (pmoles)
Hsd17b2, for T jHsd17b2,T LN (5.67610
28, 2.0)
Hsd17b2, for E2 jHsd17b2,E2 LN (5.40610
26, 2.0)
LN (geometric mean, geometric SD): lognormal distribution.
doi:10.1371/journal.pone.0053891.t005
Table 6. Modulation (fold-change) of steroidogenic enzymes mRNA levels and aromatase enzymatic activity following exposure of
granulosa cells to selected chemicals.





Direct aromatase enzymatic activity 0.9960.11 0.9460.14 0.89* 60.11 0.9860.09 0.2960.10a
Aromatase mRNA levels 1.94* 61.23 1.61* 61.15 1.0661.15 3.13* 61.04 Not measured
Hsd17b1 mRNA levels 3.04* 63.71 1.4161.62 1.3260.42 1.61* 60.80 Not measured
Fold-changes: mean 6 standard deviation.
*Statistically different from control, p,0.05.
aOdum et al., 2002 [10].
doi:10.1371/journal.pone.0053891.t006
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iterations (the last 10,000 iterations from each of the three chains).
For FSH effect on aromatase and Hsd17b1, while prior
distributions were quite vague (see Table 3), posterior distributions
indicated that the effect of FSH on aromatase is about four times
higher than its effect on Hsd17b1. Vmax and Km for aromatase had
informative priors and the posterior distributions were close to
them; this probably may confirm the prior knowledge. However,
although we used the same aromatase Vmax prior for A and T,
posterior distributions revealed a 3-fold higher Vmax for T. On the
contrary, according to posterior distributions, the aromatase Km for
A is 5-fold smaller than the one for T. The posterior distributions
for Hsd17b1 Vmax and Km were modified by a factor 1 to 2 for
jHsd17b1,E1, jHsd17b1,A, and lHsd17b1,A, and by a factor 3 for
lHsd17b1,E1. The average inter-study variability factor was about
40%. Study-specific variability factors ranged from 0.03 to about
5. The measurement error variances corresponded to a coefficient
of variation of about 65% for mRNA/protein quantities (S2), and
48% for hormone measurements (S3).
Flux Analyses of In Vitro and In Vivo Experiments
Figure 4A, B shows the results of A, E1, T, and E2 in vitro
interconversion flux analysis 48 h after addition of the substrate A
(200 nM), with or without FSH (20 ng/ml). The flux value for the
reference reaction A to E1 increased from 7.29610
29 pmoles/
min/cell (without FSH) to 8.7261028 pmoles/min/cell (with
FSH). The other reaction relative values show that the preferential
pathway for E2 synthesis in GCs in vitro is conversion of A into E1,
which is then converted into E2, both with or without FSH.
Figure 4C, D, E shows the results of steroid hormone in vivo
interconversion flux analysis at different times of the estrous cycle.
The flux value for the reference reaction A to E1 increased from
5.1061029 pmoles/min/cell at the estrus stage to 6.0961029
pmoles/min/cell at the diestrus stage and to 6.1761029 at the
proestrus stage. Those in vivo results, which show a preferential
pathway for E2 synthesis trough E1 conversion, itself coming from
A, are in accordance with the in vitro ones. Some differences
between in vitro and in vivo flux analyses can be noted, like the
greater conversion of T to E2 in vivo than in vitro, or the relative
importance of the retroconversions of T and E2 to A and E1,
respectively, in in vitro experiments compared to in vivo ones.
In Vivo Model Simulation
In order to evaluate the model accuracy, we set the GC model
parameters in vivo to the values found by calibration with in vitro
data. In vivo parameter uncertainty and variability were modeled
by distributions of hormone inputs, clearances, mRNA/protein
degradation and specific synthesis, and Hsd17b2 apparent kinetic
constant parameters (Table 5). These distributions, used in inputs
to Monte Carlo simulations, yielded predictive confidence
intervals.
We compared the model-predicted ovarian steroid concentra-
tions with the data from baseline experiments (Figure 3). The
mean of our model predictions were within the 95% confidence
interval of the model predictions. A quantitatively close profile for
predicted data and experimental data was observed for E2,
whereas the values for E1 in the diestrus stage were somewhat
under experimental data. Profiles for FSH and androgens are
shown for informative purpose, since they were constructed (using
forcing functions) to match the observed profiles.
In Vivo Experimental Results: EDC Study
Figure 5 illustrates the distribution of experimentally measured
ovarian E2 levels following EDC oral exposure. E2 levels were
significantly increased in atrazine-treated females, whereas no
statistically significant alteration of E2 was observed with bisphenol
A, methoxychlor, and vinclozolin treatment. As far as vinclozolin-
treated rats are concerned, one of those showed an elevated E2
ovarian concentration.
In vivo data extracted from the literature showed a significant
decrease of E2 in letrozole-treated rat ovaries, compared to control
[24].
Predictions for Ovarian Estradiol Concentrations in EDC-
treated Female Rats
In vitro results with atrazine, bisphenol A, methoxychlor
metabolite HPTE, and vinclozolin metabolite M2 showed a
modulation in mRNA levels after four hours of chemical exposure;
and only cells treated with HPTE and letrozole showed a
significant decrease in aromatase enzymatic activity (Table 6).
To further evaluate the predictive capacity of the model, we
simulated E2 concentrations in female rats exposed to atrazine,
bisphenol A, methoxychlor, vinclozolin, and letrozole for six
hours. After ‘‘in vivo’’ simulation with the mathematical model, we
compared E2 values predicted with those experimentally measured
(Figure 5). A two sample Kolmogorov-Smirnov test was performed
for each pair of data (experimental versus predicted data for each
treatment). It confirmed that the distributions of experimental data
and model predictions were similar for control, atrazine, bisphenol
A, methoxychlor, and letrozole treatments. Significantly different
distributions were found only for vinclozolin treatment (p = 0.021).
Discussion
The model presented here offers a detailed description of some
steroidogenic processes, focusing on what we felt to be the most
important ones for in vitro to in vivo extrapolation. The Bayesian
approach used for calibrating the model parameters permitted us
to take into account both uncertainty and variability in exper-
imental data, which is an asset for the relevance of the predictions.
The in vitro and in vivo data we generated allowed us to finely
calibrate and cross-validate the model, which was able to
quantitatively predict E2 ovarian concentration in physiological
conditions or after exposure to selected EDCs. This model, in spite
of its limitations, has many potential mechanistic or predictive
applications, as we discuss in the following.
Model Development
In the context of EDC toxicity assessment, some authors
developed systems biology models of the hypothalamic-pituitary-
gonadal (HPG) axis. Many of them are graphical systems models,
which allow researchers to visualize and think more clearly about
the impact of chemicals on the HPG axis (as reviewed by
[35,36,37]. They can also provide a framework for integration of
quantitative computational models, such as those of Breen et al.
[38], Watanabe et al. [39], and Li et al. [40]. Breen et al. [38]
proposed a steady-state model of fathead minnow ovarian
synthesis and release of T and E2; Watanabe et al.’s model [39]
simulates synthesis and feedback loops for T, 11-ketotestosterone,
E2, and vitellogenin plasma concentrations in male fathead
minnow; Li et al.’s model [40] simulate E2, T, and vitellogenin
plasma concentrations in female fathead minnow. Those models
focused on fish as a target species since endocrine disruption is well
documented in aquatic species [41]. However, the assessment of
EDC toxicity for humans warrants the development of mamma-
lian models. We chose to develop a computational model focusing
on the last steps of steroidogenesis in the rat ovary. This choice
seemed to be a good compromise between our purpose (make
quantitative in vivo predictions for a mammal based on in vitro
In Silico Model of Rat Ovarian Steroidogenesis
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measurements), and the data available to calibrate and cross-
validate our model.
Model Calibration
The calibration of the model was done on the basis of several
in vitro data sets, including our own. The diversity of protocols, in
particular for cell pre-treatment, led us to model inter-study
variability. Experiments reported in the literature were done to
compare treatments with control conditions rather than to develop
a computational model. For that reason, they lack endpoints such
as time-response curves at several FSH levels, precursor hormone
measurements, etc. In that sense, to develop a quantitative
computational model forces one to identify the kind of data
needed. Beyond answering the questions raised when developing
the model, such a refinement of experimental design may yield
new findings about cellular biology and toxicology in vitro. In any
case, the model was able to account for the differences between
studies and predicted the endpoints reasonably well. That can be
considered as the first part of our model validation process.
Model Evaluation with Cross-validation
Results from a baseline in vivo study, without EDCs, were used
to evaluate our model ability to predict some features of steroid
synthesis in normal physiological conditions. We used model
parameter values estimated by calibration of the in vitro data ‘‘as
is’’, without adjustment, to simulate E1 and E2 production by the
ovary in vivo. The results showed that the model was able to
accurately simulate ovarian E2 concentrations during normal
cycling in female rats. The results for E1 were less convincing, in
particular during diestrus. We did not go as far as to model the
ovarian steroid output, plasma concentrations, and the hypotha-
lamic-pituitary (HP) feedback. That was beyond the scope of our
work, but more importantly, modeling steroid output from the
ovaries and sex steroid plasma concentrations would have required
calibration of several more parameters and compromised the mere
feasibility of model cross-validation.
Model Predictions and Biological Insight in Baseline
Conditions
Updating the a priori parameter distributions into posteriors
gives us some insight into features of the rat sex steroid synthesis
network. For example, the preferred conversion of A into E1 by
aromatase (in spite of its conversion into T by Hsd17b1) seems due
to differences in Km values of androstedione for aromatase and
Hsd17b1, rather than to differences in Vmax values.
The flux analyses indicate that the preferential pathway for E2
synthesis involves E1 both in vitro and in vivo. They also point out
Figure 4. Flux analyses of in vitro and in vivo experiments. Graphs A and B represent the in vitro flux analysis of steroid hormones conversion
at 48 h after addition of 200 nM A into the medium, without or with FSH 20 ng/ml. Graphs C, D, and E illustrate the in vivo flux analysis of steroid
hormones conversion at several times of the estrus cycle (corresponding to diestrus, proestrus, and estrus stages). The aromatization reaction of A
into E1 is taken as the reference reaction for each condition. The flux values for that reference were 7.2961029 pmoles/min/cell in vitro without FSH,
8.7261028 pmoles/min/cell in vitro with FSH, 6.0961029 pmoles/min/cell in vivo in the diestrus stage, 6.1761029 pmoles/min/cell in the proestrus
stage, and 5.1061029 pmoles/min/cell in the estrus stage of the estrous cycle. Values for the other reactions in each condition are relative to the
corresponding reference. Arrow thicknesses are proportional to the flux absolute values.
doi:10.1371/journal.pone.0053891.g004
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the need to perform toxicity testing experiments under FSH-
controlled conditions.
Flux analyses show clear differences between in vitro and in vivo
conditions. For example, steroid inactivation reaction fluxes (T to
A and E2 to E1) are ranged from 10
23 to 1026 pmoles/min/cell
in vitro, and ranged from 1024 to 10212 pmoles/min/cell in in vivo
conditions. Those differences can be explained by differences in
hormone inputs to the system. Fluxes depend on reaction
parameter values and hormone inputs applied. We showed that
keeping parameter values equal in vitro and in vivo, and simply
changing hormone inputs, is enough to explain flux differences
between in vitro and in vivo conditions.
Model Predictive Capacity Evaluation with Selected EDCs
To further evaluate the model predictive capacity, we simulated
in vivo steroid concentrations in the ovaries after chemical exposure
and compared them to original experimental results. Simulations
were performed by modifying aromatase Km or mRNA levels on
the basis of transcriptomic and enzymatic activity data obtained
in vitro for GCs. We limited our predictions to six hours post-
exposure, a period during which feedback regulation can be
assumed to be negligible.
Results show that our model predictive capacity was different
according to treatment. Model predictions were found to follow
the same distributions as the experimental data, except for
vinclozolin. However, Figure 5 shows nuances between treat-
ments. The model predicted reasonably well the early ovarian
response in E2 concentration for adult female rats exposed to
atrazine and letrozole. Atrazine and letrozole mechanisms of
action can explain why their effects were the most clearly seen
experimentally and the best predicted by the model after a few
hours. Indeed, we have previously shown [27] that elevated
aromatase mRNA expression (see also Table 6) and the
subsequent increase in aromatase catalytic activity in atrazine-
treated females explain a large part of the increase in estrogen
levels. As far as letrozole is concerned, it was designed to be a
specific aromatase inhibitor. The early ovarian responses in E2
concentration for adult female rats exposed to bisphenol A,
methoxychlor, or vinclozolin were less well predicted. The effects
of bisphenol A, HPTE, or vinclozolin M2 on aromatase or
Hsd17b1 did not explain the in vivo modulation of estrogen levels
following treatment, although they can significantly affect enzyme
mRNA levels in vitro. Instead we previously hypothesized that the
main mechanisms of action are: a disruption of the hypothalamic-
pituitary-adrenal axis for methoxychlor and vinclozolin; a
peripheral effect on conjugation/deconjugation metabolism pro-
cesses for bisphenol A [27]. The model, which doesn’t predict very
well variations of E2 concentrations following exposure to those
three chemicals, may confirm that the effects on granulosa
steroidogenesis are not predominant. Furthermore, vinclozolin
predictions were less precise, and showed higher variability. That
is actually an interesting feature: vinclozolin mechanism of action
is known to be more complex, acting notably by its anti-
androgenic metabolite M2 [4], and subject to variable amplifica-
Figure 5. Experimental data vs predictions of estradiol levels in control and EDC-treated female rats at the diestrus stage.
Experimental data are represented by points (n = 8 for control data, n = 4 for EDC-treated animals data). Statistical distributions of the model
predictions are represented by boxplots (showing the distribution quartiles). Control is for atrazine 200 mg/kg, bisphenol A 200 mg/kg, and
vinclozolin 100 mg/kg; control 2 is for letrozole 5 mg/kg. ATZ: atrazine; BPA: Bisphenol A; MXC: methoxychlor; VCZ: vinclozolin; LET: letrozole.
doi:10.1371/journal.pone.0053891.g005
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tion in the steroidogenesis pathway. The experimental data
themselves showed higher variability for vinclozolin, although
the small number of animals tested precludes strong conclusions.
Even if predictions for E2 levels compared well with exper-
imental values, the usefulness of the model could be improved.
First, it does not account for EDC effects on androgen precursors,
and can only predict effects for chemicals that act on the last steps
of steroidogenesis. An improvement would be to add other
pathways to the mathematical model, such as steroidogenic
processes in thecal cells. The model may also integrate effects on
steroid receptors, like the estrogen one, which is the target of
numerous chemicals [42]. The model also lacks numerous
feedbacks, in particular those mediated by the HP axis. Thereby,
for now, the model predictions for steroid ovarian concentrations
are of limited value for a complete analysis of endocrine
disruption. Rat HP axis feedback models previously described
[43,44] might be useful for coupling with ours.
Model Potential
Despite the limitations discussed above, the model perspectives
are multiple. All the reaction parameters can be modulated to
reflect changes observed in vitro, for example. That approach can
be very useful for investigating mixture and chronic effects. It can
also help formulate hypotheses and design experiments aimed at
understanding the mechanisms of endocrine toxicity, notably for
the effects which follow a non-monotonic dose-response, like those
of EDCs. A model integrating feedback regulations would permit
to describe further targets, such as the HPG axis, enzyme
inhibition, or local gene expression effects.
Observations of alterations in ovarian functions at molecular
and biochemical levels are useful for regulatory decision-making
only if these changes can be translated into effects at higher
biological levels of organization. The model is able to make
quantitative predictions about steroid secretion based on data on
the impact of chemicals on the last steps of ovarian steroidogenesis.
Sex steroid concentration changes, even of low scale, account for a
large part of effects in reproductive toxicology, but it is not
sufficient. Integrated models, predicting multiple endpoints
relevant for reproductive toxicology assessment, have been
developed in the fathead minnow [39,40]. Since links between
sex steroid concentration changes and reproductive toxicity are
not clear in mammals, some work still has to be done.
Conclusions
The model developed was able to predict a very sensitive and
integrative reproductive endpoint: ovarian sex steroid levels, from
in vitro data. The results of flux analyses and predictions of EDC-
treated females show that the model not only fits the data
empirically, but also captures major features of the GC
steroidogenesis network. We carefully limited the scope of our
model to ovarian secretion in order to be able to cross-validate it
with the data available. In some cases, investigating effects simply
on gonads can be a powerful tool for understanding whole-body
hormone disruption, in which case the model might be a valuable
tool for toxicity assessment. While the predictive capacity of this
mathematical model is still limited, it already has potential
applications for improved evaluation of endocrine disruption
following chemical exposure, in particular for low levels and
mixtures of pollutants.
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